Clinical trial
Dosing Study of Ara-C/EL625/Idarubicin in Refractory and Relapsed AML
NCT00074737 · Eleos, Inc., Industry · Completed
Key facts
| NCT number | NCT00074737 |
|---|---|
| Title | Dosing Study of Ara-C/EL625/Idarubicin in Refractory and Relapsed AML |
| Official title | Open Label, Phase II Dosing Study of Ara-C Chemotherapy in Combination With EL625 and Idarubicin in Refractory and Relapsed Acute Myelogenous Leukemia (AML) |
| Lead sponsor | Eleos, Inc., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Acute Myelogenous Leukemia |
| Intervention type | Drug |
| Interventions | cenersen, Idarubicin, Cytarabine |
| Enrollment | 53 |
| Start date | Apr 1, 2004 |
| Primary completion | May 1, 2007 |
| Completion | May 1, 2007 |
| First posted | Dec 23, 2003 |
| Last update posted | Sep 18, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: